Category 13

AI Biotech & Drug Discovery

Computational biology and drug discovery.

Standout picks across editions

The current edition's pick, highlighted, plus earlier picks in this category from our backfilled archive — sourced from credible outlets (Hacker News, GitHub, TechCrunch and more) and checked against each product's official site.

This edition's pick · Nov 16–30, 2026
IL

Isomorphic Labs

AI-first drug discovery heading to the clinic

AI drug discovery; $5B raised to reach clinic.

Why it matters

A $5B Series C (Nov 17) to move AI-designed drugs toward clinical trials is the edition's defining biotech-AI event — though funding is a signal, not proof of clinical success.

Oct 16–31, 2026 edition
FB

Formation Bio

AI drug developer with a $600M stalled-drug fund

AI-driven drug developer; $600M fund to revive stalled drugs.

Formation Bio is an AI-driven drug development company that, in October 2026, launched a $600M fund to buy or license drug candidates that have stalled — betting it can use AI and a tech-enabled development model to revive and advance them. The move pairs capital with its AI development engine to prove out that thesis. (Reported by Forbes; details not independently deep-verified here, and funding is a supporting signal, not proof of clinical success.)

Why it mattered

A novel AI-biotech strategy — a $600M fund to rescue stalled drugs — reported by Forbes as an Oct 2026 move, distinct from the usual discovery-stage raises.

Evidence dated 2026-10-28news ↗official ↗
Researched · pending approvalVisit site ↗

How picks are selected

Candidates are scored on market traction, recent momentum, product innovation, community interest, practical usefulness and source credibility. Only researched, fact-checked products are published — if no candidate meets the evidence threshold, we show no pick rather than forcing a weak selection.